Lumos and BARDA Partnership - Investor BriefingMELBOURNE,...

Lumos and BARDA Partnership - Investor Briefing

MELBOURNE, Australia 9 October 2024 – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a
leader in rapid, point-of-care diagnostic technologies, is pleased to invite investors to an online briefing
session on Friday, 11 October 2024, at 10.30am AEDT.

During the session, Lumos CEO and Managing Director, Doug Ward and Vice President of Medical Affairs,
Annie Bell will further discuss the news (ASX: 3 October 2024) that Lumos and the U.S. Biomedical
Advanced Research and Development Authority (BARDA) have partnered to support the coming FebriDx®
CLIA waiver study and US FDA application. The discussion will also cover plans for the coming CLIA waiver
study and the non-dilutive funding awarded to Lumos.